Third-generation antivenomics analysis of the preclinical efficacy of Bothrofav® antivenom towards Bothrops lanceolatus venom
Davinia Pla,
Yania Rodríguez,
Dabor Resiere,
Hossein Mehdaoui,
José María Gutiérrez,
Juan J. Calvete
Affiliations
Davinia Pla
Laboratorio de Venómica Evolutiva y Traslacional, Instituto de Biomedicina de Valencia, CSIC, Jaime Roig 11, 46010 Valencia, Spain
Yania Rodríguez
Laboratorio de Venómica Evolutiva y Traslacional, Instituto de Biomedicina de Valencia, CSIC, Jaime Roig 11, 46010 Valencia, Spain
Dabor Resiere
Service des Urgences et de Reanimation Polyvalente, Centre Hospitalier Universitaire, Fort-de-France, Martinique, France
Hossein Mehdaoui
Service des Urgences et de Reanimation Polyvalente, Centre Hospitalier Universitaire, Fort-de-France, Martinique, France
José María Gutiérrez
Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica; Corresponding author.
Juan J. Calvete
Laboratorio de Venómica Evolutiva y Traslacional, Instituto de Biomedicina de Valencia, CSIC, Jaime Roig 11, 46010 Valencia, Spain; Corresponding author.
Bothrops lanceolatus inflicts severe envenomings in the Lesser Caribbean island of Martinique. Bothrofav®, a monospecific antivenom against B. lanceolatus venom, has proven highly effective at the preclinical and clinical levels. Here, we report a detailed third-generation antivenomics quantitative analysis of Bothrofav®. With the exception of poorly-immunogenic peptides, Bothrofav® immunocaptured all the major protein components. These results, along with previous preclinical and clinical observations, underscore the high neutralizing efficacy of the antivenom against B. lanceolatus venom. Keywords: Bothrops lanceolatus, Antivenom, Snake venom, Bothrofav®, Third-generation antivenomics, Martinique
